Foundation for Innovative New Diagnostics Find

“Individuals employed by FIND are not US residents or US employees. Information pertaining to the number of employees and employee compensation is provided using the best information available from equivalent W-2 & W-3 forms for the various countries in which FIND employs individuals. The number of employees reported on the 2020 Form 990 included employees for two related organizations. There is a reduction in the number of employees reported in 2021 as the total number of employees represents only those employed by Foundation for Innovative New Diagnostics and excludes those employed by related organizations.”

“FORM 990 REVIEW PROCESS The Form 990 is prepared by an independent accounting firm and reviewed by the director of finance. Once approved by the director of finance, the Form 990 is also reviewed by the CEO.”

“FINDs conflict of interest policy requires directors, officers and key employees, all other staff members, board members, consultants and partners to disclose actual or potential conflicts of interest when they arise. The person or company is also required to recuse themselves from any decision making.”

“COMPENSATION REVIEW A review by an independent consultant of the CEO's remuneration package was done by the Board and forms the basis of a written employment contract. Remuneration terms for officers and key employees are based on market rates for similar positions in specific locations. This benchmarking is done against an independent report which presents data collected for similar organisations and this exercise is done every 3 years. Salaries for all staff are available to the Board and Compensation Committee. However, the salaries of the C-suite and other key staff are approved by the Compensation Committee.”

“AVAILABILITY OF GOVERNING DOCUMENTS TO THE PUBLIC Upon request FIND's governing documents (Statutes and By-Laws) Conflict of Interest policy and Financial Statements are available for inspection at FIND's offices in Geneva, Switzerland.”

“Books in care of phone number The telephone number of the person who possesses the books and records is: +41 (22) 710 05 90.”

“The organization's telephone number is +41 (22) 710 05 90.”

“This represents programe service for AMR, Access, Fever & Malaria and Pandemic Preparedness. A summary of each program is given below. PROGRAM - AMR: Expenses - $6,253,526 including grants of $2,979,937 Our AMR work is delivered under the broad programme of Pandemic Threats. In 2021, a rapid test for the detection of Neisseria gonorrhoea was successfully developed and is now ready for transfer to manufacturing and commercialization. Performance met target product profile requirements, including in asymptomatic patients. Test usability was also assessed in South Africa. By the end of 2021, 2 of the 28 products in FIND's product development pipeline (excluding COVID-19 products) were for AMR with one in development stage and the other in evaluation stage. We completed three clinical trials in AMR and three were ongoing. PROGRAM Access - Expenses - $4,695,731 including grants of $1,512,689 The scope of FIND access work is broad with multiple focus areas ultimately enabling access to testing. In 2021, FIND was especially focused on its role in supporting global access to COVID-19 tests and genomic sequencing, through its role in the Access to COVID-19 Tools Accelerator Diagnostics Pillar (ACT-A Dx). As part of country engagement work, FIND initiated catalytic work with local partners in 30+ countries for access innovations-supporting countries to embed testing and surveillance into national health strategies. For TB, a community screening project in India enhanced access to TB services through women-led self-affinity groups (SAGs), targeting people at high risk of developing TB. PROGRAM - Fever Expenses - $2,244,930 including grants of $757,236 Our focus on febrile illnesses is to deliver diagnostic tools and strategies that improve triage and differential diagnosis at the first levels of health systems for timely referral of severe infection and to inform appropriate treatment for different diseases (including typhoid, dengue, malaria, pneumonia, and COVID-19). By the end of 2021, 6 of the 28 products in FIND's product development pipeline (excluding COVID-19 products) were for fever with one in development stage and five in evaluation stage. FIND evaluated 16 alternate biomarkers for fever, none of which outperformed C-reactive protein (CRP). PROGRAM - Pandemic Threat Expenses - $2,464,280 including grants of $1,666,046 Our work here focused on strengthening diagnostic surveillance and response systems to contain outbreaks and improve pandemic preparedness, aligned with a One Health approach. Under our broader health emergency work, we also made progress on leveraging digital tools and next-generation sequencing and genomics. Pandemic Preparedness was a major topic that brought together governments, FIND, key global health agencies and industry. Looking at initial learnings from the COVID-19 pandemic, the G7, led by the UK and its Chief Scientific Officer, Patrick Vallance, developed an ambitious product development strategy dubbed the "100 Days Mission". FIND was asked to manage the diagnostics component of this "moon-shot mission", in a partnership led by CEPI. This provided both the anchoring of our future pandemic work as well as a key partnership for our alliance, and we supported efforts to fund this important work through the CEPI replenishment. Several industry roundtables related to the 100 Days Mission have been organized with FIND. By the end of 2021, of the 28 products in FIND's product development pipeline (excluding COVID-19 products), 2 were for non-COVID pandemic threats. Some of the strategic outcomes of our pandemic preparedness program included strengthening LMIC capacity to perform tests and use testing data and promoting alliance that provides end-to-end capacity needed to achieve objectives for equitable access to diagnosis.”

“Prior period adjustment to exclude net assets of related organizations.”